The Global Point-of-care (POC) Diagnostics was valued at USD 50.09 billion in 2023 and is projected to reach approximately USD 120.35 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.16% from 2024 to 2033.
Point-of-Care Diagnostics refer to medical tests conducted near the site of patient care, allowing for quick results. These tests can be performed by healthcare professionals or, in some cases, by patients themselves. The primary drivers of market growth include the increasing demand from both healthcare providers and patients for faster, more accessible testing options. This market encompasses a broad array of diagnostic products, including glucose monitors, infectious disease tests, and cardiac markers, designed for use in various settings, such as hospitals, clinics, home care environments, and ambulatory care facilities.
A key factor influencing the demand for Point-of-Care Diagnostics is the global prevalence of conditions like HIV. According to the World Health Organization (WHO), as of the end of 2023, an estimated 39.9 million people were living with HIV worldwide. Approximately 0.6% of adults aged 15-49 are affected by HIV, though the impact of the epidemic varies significantly across different countries and regions. This ongoing healthcare challenge underscores the need for accessible, rapid diagnostic solutions, which are expected to drive growth in the POC diagnostics sector over the coming decade.
In 2023, the North America region led the market, holding the largest revenue share at 42.70%. Europe followed with a significant share of 28.90%. In terms of product types, the infectious disease testing segment was the dominant contributor, accounting for 27.60% of the total revenue.
When considering end users, clinics and hospitals represented the largest share, capturing 63% of the revenue in 2023. Regarding delivery methods, prescription-based testing emerged as the leading mode, with a 54% revenue share.